| Abstract |
Three aspects of the production and applications of monoclonal antibodies
(mabs) were investigated. Two new cell lines (C23/11 and HET-37) were
produced for use as potential fusion partners in human mab production.
C23/11 was established from a blood sample obtained from a patient with
myeloma. It was shown to have many of the cellular and antigenic
properties associated with a lymphoblastoid cell line. HET-37 is a
human/murine heteromyeloma cell line which was established after C23/11
cells were fused with murine NSO cells. Both C23/11 and HET-37 were
characterised using electron microscopy, histology, immunophenotyping,
isoenzyme analysis and DNA fingerprinting. In the second experimental
section, three mab (HMFG-1, AUA-1 and H17E2) were labelled with the
radioactive isotope, Indium-III. They were used for localisation of tumour
in 21 patients with suspected ovarian carcinoma. (III)In-mab
immunoscintigraphy was found to be a more sensitive technique for
evaluation ovarian cancer than X-ray, CAT scan and ultrasound. (III)In-mab
immunoscintigraphy was particularly useful in localising tumours in
patients with serum CA-125 levels greater than 100 IU/ml. F(ab')2
fragments of HMFG-1 were labelled with technetium and were used to
determine the distribution of ovarian tumour in a patient with minimal
residual disease. In the final experimental section, HMFG-1 was chemically
conjugated to the photosensitiser hematoporphyrin, Hp. HMFG-1-Hp was shown
to kill antigen-bearing MCF-7 cells in vitro after irradiation. The
HMFG-1-Hp conjugate had no effect on EJ-138 cells under identical conditions. The
EJ-138 cell line does not express the antigen to which the HMFG-1 antibody
binds.
|
|---|
